ACTH-fragment nootropics: what we know

Every peptide sold online as an ACTH-fragment nootropic traces back to one hormone. Adrenocorticotropic hormone, or ACTH, is the pituitary signal that drives cortisol release from the adrenal gland, and pharmacologists spent decades cutting it into short stretches to test whether the behavioural effects reported for the whole molecule could be separated from the hormonal ones. Semax is the best known compound to come out of that line of work, and the literature describes it as a synthetic analogue of the ACTH(4-10) fragment^[1]. This is what the class has actually shown in humans, and where the record stops.

What the class is, and what it is deliberately not

The compounds in this family are described in the pharmacology literature as noncorticotropic analogues of the ACTH(4-10) fragment^[1]. They carry a short piece of the ACTH sequence without the adrenal-stimulating action of the parent hormone, which is the entire point of the design. Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro^[2]. Org 2766 is a different member, an ACTH(4-9) analogue that was taken into nerve-protection trials in cancer patients rather than into cognition work^[3]. Melanotan II is also grouped with the ACTH(4-10) analogues, but it is a potent melanocortin receptor agonist^[1], which puts its behaviour closer to PT-141 than to the nootropic end of the family. One parent hormone, three different pharmacological destinations.

The parent fragment was tested in people, and it made things worse

ACTH(4-10) itself has been given to healthy adults. Smolnik and colleagues studied 60 healthy participants in 2000, using either a single 1 mg intranasal dose or 1 mg daily for six weeks, and measured event-related brain potentials during an auditory vigilance task alongside word recall^[4]. ACTH 4-10 raised error rates during the vigilance task and impaired recall of neutral words. The authors concluded that the peptide produced an impairment in differential processing of relevant versus irrelevant contents within the working memory^[4]. That points the opposite way from the marketing. It is one study on the unmodified fragment rather than on Semax, so it does not settle the class question on its own, but anyone claiming a clean cognitive benefit for ACTH fragments in humans has to account for it.

Org 2766 got Western trials, and they came back flat

The only member of this family with a Western randomised trial programme behind it is Org 2766, and the target was chemotherapy nerve damage rather than memory. A Cochrane review by Albers and colleagues, published in 2014, identified four randomised controlled trials covering 188 participants treated with Org 2766 against 123 controls. Pooling the three trials that used comparable measures, the reviewers reported no significant vibration perception threshold neuroprotection^[3]. That result matters for the whole class, because it is the one place these peptides were held to a full randomised standard with quantitative sensory testing as the endpoint, and the pooled effect did not survive it.

Semax carries the clinical record, and it is a Russian one

The human evidence people mean when they talk about this class is Russian, and most of it concerns stroke recovery rather than cognitive enhancement in healthy adults. Gusev and colleagues followed 110 post-stroke patients in 2018 (43 men and 67 women, mean age 58.0 plus or minus 9.7 years) through early and late rehabilitation. The regimen the paper calls standard is two 10-day courses at 6,000 micrograms a day separated by a 20-day interval, and the authors reported higher plasma brain-derived neurotrophic factor, faster functional recovery on the Barthel index, and better motor performance on the British Medical Research Council scale^[5]. The mechanistic work sits mostly in rodents. Eremin and colleagues reported that Semax raised striatal serotonin metabolite content by 25% within two hours, with extracellular levels rising to roughly 180%, and that it did not move dopamine on its own but amplified the dopamine release triggered by amphetamine^[2]. Our Semax page works through that literature in detail.

Publication volume is easy to mistake for evidentiary depth. A PubMed search for semax returns 230 results^[6]. The same term returns zero registered studies on ClinicalTrials.gov^[7], and the EU Clinical Trials Register answers that the query did not match any clinical trials^[8]. DailyMed, the US drug-label database, holds no package labels for it at all^[9]. A large literature sitting next to an empty trial register is a specific pattern: mechanism papers, small single-centre clinical reports, and nothing that a Western regulator has ever been asked to assess. The regulatory position outside Russia follows directly from that.

What we don't yet know

No published study has compared the class members head to head inside one protocol. There is no dose-response curve for cognitive endpoints in healthy adults, and the route that produced the clinical numbers is intranasal, not the subcutaneous injection that most online discussion assumes. Safety across months to years of continuous use has not been characterised in any pharmacovigilance system in our coverage area. A 2026 review of therapeutic peptides in aging that includes Semax states the position plainly: non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation^[10]. The supply problem is the one that applies to BPC-157 and ipamorelin as well. Without a batch certificate of analysis, what is in the vial is an assumption, not a fact.

Where this leaves you

Read this family as three separate stories rather than one category. The parent fragment has a human study that found impairment. Org 2766 has a Western trial record that came back null. Semax has a Russian clinical record with real reported effects and a methodology that no regulator outside Russia has examined. The jurisdiction-by-jurisdiction picture is on the regulation pages for the United States, the United Kingdom, Germany, Denmark, the Netherlands, Sweden and Norway.

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed here may be classified as prescription medicines or research chemicals depending on your jurisdiction. If you are considering anything in this class, that is a conversation for a qualified healthcare professional who knows your medical history. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.